Consistent benefits of apixaban over warfarin were also seen for major bleeding in East Asian ( HR 0.53 , 95 % CI 0.35-0 .80 ) and non-East Asian ( HR 0.72 , 95 % CI 0.62-0 .83 ) patients ( interaction P = .17 ) .